Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-867: pembrolizumab plus SBRT versus placebo plus SBRT in unresected stage I-II NSCLC
NL-OMON52095Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + SBRT with Placebo + SBRT (2 arms). Primary endpoints: Event-free survival and Overall survival. Started Aug 2022; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52095.